Blood platelets play a fundamental role in hemostasis and thrombosis. The physiological role of platelets is to preserve the integrity of the cardiovascular system such that upon injury platelets are activated and serve to interrupt a potentially deleterious situation (i.e., hemorrhage). However, platelets are also involved in the pathophysiology of thrombosis in which the normal repair process is grossly exacerbated, resulting in interruption of blood flow to vital tissues. Thus, a critical balance exists between the normal function of blood platelets to preserve tissue function and a pathophysiological function in which tissue is damaged due to thrombosis and subsequent ischemia. Numerous anti-platelet agents have been developed in an attempt to interrupt the thrombotic process without severely compromising the hemostatic state of patients. This article will be devoted to a discussion of a commonly utilized anti-thrombotic agent, aspirin, as well as a class of newer, possibly more effective anti-thrombotic agents referred to collectively as fibrinogen receptor antagonists.
INTRODUCTION
Approximately 1.5 million persons per year experience a myocardial infarction in the United States. In 1980, DeWood et al (12) made the seminal observation that thrombosis at the site of a pervious vascular atherosclerotic narrowing is an important factor in acute occlusion of diseased blood vessels.
Thus, the search began in earnest for agents that would have a spectrum of activity greater than that achieved with standard anti-platelet drugs such as aspirin and dipyridamole (Table I ). Aspirin has been demonstrated to exert salutary effects on prevention of various platelet-mediated cardiovascular conditions and will be the subject of much of this article.
However, attention will also be focused on a newer class of agents, namely, fibrinogen receptor antagonists, which may have an advantage over aspirin. Aspirin prevents only thromboxane-mediated platelet aggregation and does not affect aggregation in response to agents like thrombin, epinephrine, serotonin, and primary wave ADP. Fibrinogen receptor antagonists block the platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor, which binds plasma fibrinogen upon platelet agonist stimulation, irrespective of which agonist is utilized. Thus, fibrinogen receptor antagonism exhibits a broad spectrum of anti-platelet activity against all known platelet agonists, as GPIIb/IIIa binding of fibrinogen is a final common pathway of platelet aggregation.
METHODS
Platelet function can be assessed in vitro, in vivo, and ex vivo. Only by combining all of these techniques can the true potential of any given agent be thoroughly evaluated. The following are generally accepted methods for performing platelet function studies.
In Vitro Platelet Aggregometry. Whole blood is obtained from the species of choice generally by venipuncture into a plastic syringe containing 1 part 3.8% trisodium citrate to 9 parts blood. Plateletrich plasma is then obtained by centrifugation at 100-200 x g for 10 min at room temperature. Platelet count is usually adjusted to 250,000-300,000/~1 by addition of platelet-poor plasma that is obtained by high-speed centrifugation of whole blood. Adjusted platelet-rich plasma samples of appropriate volume (250-500 ~1) are then warmed to 37°C in siliconized cuvettes. Platelet agonists such as ADP, serotonin, thromboxane, epinephrine, thrombin, collagen. arachidonic acid. or Dlatelet-activatin~ fac-tor are then added to the sample, and light transmission aggregometry is performed. Light transmission aggregometry is a well-accepted method of measuring platelet function in which a beam of light is passed through the cuvette. Platelets in solution are turbid, and when an agonist is added to the sample the platelets aggregate, which triggers a pen recorder by allowing more light to pass through the cuvette. Thus, using this methodology it is possible to construct concentration-response curves for various platelet agonists and then study potential inhibitors of platelet aggregation by addition of the inhibitor to the cuvette before addition of a given agonist.
In Vivo Platelet Aggregation. In vivo platelet aggregation is best studied in a canine model originally described by Folts et al (17) and further characterized by Aiken and Shebuski (1) . This model relies on placement of a plastic cylinder that inflicts a severe (80-90%) critical stenosis on the coronary artery of the dog while simultaneously monitoring coronary blood flow. Endothelial damage is also induced by rubbing and pinching the site of stenosis. The combination of endothelial damage and severe stenosis results in platelet-dependent thrombus formation as platelets initially adhere to the exposed subendothelium and then aggregate. These events lead to a progressive decline in coronary blood flow as the vessel lumen becomes plugged with platelet aggregates. The platelet plug can then be dislodged by gently moving the plastic cylinder back and forth until coronary blood flow is restored. This process occurs every 2-3 min and results in a pattern of coronary blood flow referred to as cyclical flow reductions (CFRs). CFRs are truly platelet-dependent, as heparin and fibrinolytics are ineffective in blocking their formation and only platelet inhibitory drugs such as aspirin, prostacyclin, ketanserin, OKY 1581 1 (thromboxane synthase inhibitor), sulotroban (thromboxane receptor antagonist), and fibrinogen receptor antagonists are effective in this model. Thus, this technique serves as a screen for potential platelet inhibitory drugs that have shown activity in vitro and require further evaluation in vivo.
Many other models of thrombosis have been described and have variable degrees of platelet involvement. Whereas the CFR model is exclusively platelet-dependent, many others have a fibrin component as well and, thus, are useful for evaluation of novel fibrinolytics. For a more complete description of the CFR model as well as other models of thrombosis and thrombolysis, the reader is referred to a recent review by Bush and Shebuski (3) .
Ex Vivo Platelet Aggregation. Ex vivo platelet aggregation refers to obtaining blood from subjects that have received platelet inhibitory drugs for as- 
Aspirin
Cyclooxygenase is the key enzyme responsible for synthesis of the proaggregatory and vasoconstrictor agent thromboxane A2, which is derived form arachidonic acid (AA). AA is a normal constituent of membrane phospholipids and is converted to the unstable endoperoxide intermediate, prostaglandin H2 (PGH,), by the cyclooxygenase enzyme. PGH2 is then converted via thromboxane synthase in the platelet to thromboxane A2 and via prostacyclin , synthase in the blood vessel wall to prostacyclin ( Fig. 1 ). Thromboxane is a potent pro-aggregatory and vasoconstrictor substance, whereas prostacyclin is anti-aggregatory and vasodilates blood vessels. Aspirin and other nonsteroidal anti-inflammatory drugs inhibit the cyclooxygenase and thereby eliminate prostaglandin biosynthesis such that thromboxane and prostacyclin synthesis is terminated. ' Blood platelets, with a life span of 7-10 days, are . inhibited for the duration of the platelet in the circulation and cannot synthesize new enzyme because : the platelet is a nonnucleated cell. However, en-; dothelial and smooth muscle cells in the blood ves-. sel wall are nucleated and can synthesize new en-Vd',5UL;Ui I' iLFIULU I vasoollaror I Fm. 1-Arachidonic acid metabolism in platelets and blood vessels. Cyclooxygenase inhibitors (=) prevent conversion of arachidonic acid to the unstable intermediate, PGH,, thereby eliminating both thromboxane and prostacyclin formation. Thromboxane synthase inhibitors (=) prevent conversion of PGHZ to thromboxane, thus offering a degree of selectivity in preservation of prostacyclin formation. However, PGH, itself may substitute for thromboxane in its absence. Thromboxane receptor antagonists (D) block the action ofPGH2 and thromboxane on PGH/TxA2 receptors on platelets and vasculature. zyme such that recovery of prostacyclin synthesis over time is possible.
Aspirin has been demonstrated to exert a protective effect in various platelet-mediated cardiovascular conditions. Aspirin has been convincingly shown to reduce stroke and death in men with transient ischemic attacks (5, 13) , myocardial infarction and death in patients with unstable angina (4, 29) , thromboembolic complications associated with artificial heart valves (2, 11) , and thrombotic occlusion of silicone rubber arteriovenous cannulae of uremic patients undergoing hemodialysis (23) . Furthermore, the Physicians Health Study, which was a randomized, double-blind trial in which aspirin (325 mg every other day) was compared to placebo for primary prevention of cardiovascular disease, determined that there was a 44% reduction in the overall risk of myocardial infarction (43) . Since aspirin confers a moderate degree of protection for patients with a previous history of unstable angina and myocardial infarction, it was of interest to determine whether or not aspirin was effective in the early hours of an evolving infarct. Hence, ISIS-2 (Second International Study of Infarct Survival) randomized over 17,000 patients with suspected myocardial infarction to receive streptokinase (1.5 million units), aspirin (162 mg oral), both, or neither. Again, aspirin exerted a protective effect with patients receiving aspirin experiencing a 23% reduction in risk of death (27) . These results were irrespective of whether or not the patient had also received anticoagulant therapy with heparin.
As mentioned previously, aspirin prevents formation of the pro-platelet aggregatory substance thromboxane. However, aspirin and other cyclooxygenase inhibitors also have the potential to inhibit prostacyclin formation, which is anti-aggregatory and of possible benefit in preventing thrombosis. Thus, strategies have been developed in an attempt to inhibit thromboxane formation while leaving prostacyclin formation relatively unaffected or at least recoverable. Acetylation of platelet cyclooxygenase by aspirin is dose-dependent, cumulative, and irreversible. Single doses of aspirin of 12, 20, 40, 100, and 325 mg inhibit serum thromboxane B2 (stable serum metabolite of thromboxane A2) by 30, 50, 77, 95, and 99%, respectively (33, 35, 44) . Ingestion of 20 mg of aspirin daily for 7 days inhibits serum thromboxane by more than 90% in healthy subjects (16) and in patients with atherosclerosis (45) . However, prostacyclin production by aortic tissue removed at operation from patients who had ingested 20 mg of aspirin daily for 7 days was inhibited by 50% (16) . Thus, it is unlikely that any dose of standard aspirin can maximally inhibit thromboxane generation without also reducing endogenous biosynthesis of prostacyclin.
Recently, in an effort to improve on the selectivity of aspirin as an inhibitor of platelet thromboxane without profound inhibition of vascular prostacyclin formation, a new controlled release aspirin preparation has been evaluated in humans (7) . Maximal inhibition of platelet thromboxane A2 production was sustained during long-term dosing with controlled-release aspirin, whereas basal prostacyclin biosynthesis fell only slightly and systemic synthesis of prostacyclin stimulated by bradykinin was preserved. These data indicate that controlled-release aspirin (formulation of 75 mg of aspirin released at a rate of 10 mg/hr) may facilitate determination of the clinical importance of preserving prostacyclin during platelet inhibition with aspirin in humans.
Serum thromboxane levels are of little value in predicting in vivo generation of thromboxane and are only of use in determining ex vivo generation of thromboxane by platelets. Thus, methodology has been developed to measure the urinary metabolites of thromboxane and prostacyclin as a measure of endogenous formation of these prostanoids. Urinary excretion of 2,3-dinorthromboxane B2 was reduced by 70-75% following long-term aspirin administration of 20-40 mg daily (16) . Studies have confirmed that the relationship between the capacity of the platelet to generate thromboxane ex vivo (serum levels) and endogenous formation of thromboxane in vivo is not linear and that unless at least 95% inhibition of serum thromboxane formation is achieved, biosynthesis of thromboxane is maintained to a substantial degree (37) . Due to the potent and ubiquitous nature of thromboxane, it has been further demonstrated that by increasing the degree of inhibition of platelet thromboxane formation with aspirin from 95 to 99%, measurable additional inhibition of ADP-induced platelet aggregation resulted (16) . Upon termination of aspirin treatment, serum thromboxane levels return to predosing levels within 7-10 days, regardless of the dose of aspirin administered (6, 33, 34) . The recovery phase is characterized by a lag period of 24-48 hr, which has been attributed to acetylation of megakaryocytes by aspirin (6) .
The use of aspirin has become more prevalent recently in treatment of unstable angina and evolv-ing myocardial infarction due to observations in these patient populations that thromboxane biosynthesis is much higher than expected. In patients with unstable angina, 84% of the episodes of chest pain were associated with phasic increases in the excretion of thromboxane and prostacyclin metabolites in the urine (15) . Patients with chronic, stable angina exhibited no increase in the formation of thromboxane. Quite striking increases in thromboxane production have been seen following thrombolytic therapy with streptokinase and may actually represent a complicating factor in failure to reperfuse vessels and in the high rate (20-30%) of thrombotic reocclusion that occurs following successful recanalization (14) . These indications represent acute situations in which rapid inhibition of thromboxane biosynthesis is desirable; thus, aspirin has become the agent of choice as cyclooxygenase blockade is readily achieved. However, the doses of aspirin presently utilized clearly have implications for inhibition of both thromboxane and prostacyclin. The lack of selectivity with aspirin in regard to thromboxane and prostacyclin biosynthesis has led to efforts to produce drugs that inhibit only the biosynthesis or actions of thromboxane and leave the biological actions of prostacyclin intact.
Fibrinogen Receptor Antagonists
Upon platelet activation with various mediators of platelet aggregation (ADP, serotonin, thromboxane A2, epinephrine, thrombin, collagen, plateletactivating factor), the platelet receptor for fibrinogen, glycoprotein IIb/IIIa (GPIIb/IIIa), is expressed (Fig. 2) . The tripeptide arginine-glycine-aspartic acid (RGD), which occurs twice in the Aa chain of fibrinogen, is believed to mediate at least in part binding of fibrinogen to the GPIIb/IIIa complex (19, 28) . Thus, binding of fibrinogen to activated platelets is a key event in platelet-platelet interaction and plays a major role in thrombus formation.
Pharmacological agents that interrupt the interaction of plasma fibrinogen with the platelet GPIIb/ Illa complex have been developed. These agents either are monoclonal antibodies directed against GPIIb/IIIa or are peptide or nonpeptide mimetics of RGD that block the binding of fibrinogen to the GPIIb/IIIa complex. These agents are devoid of hemodynamic effects and appear to be important new anti-thrombotic compounds, many of which are under or awaiting clinical evaluation (Table II) .
A murine monoclonal antibody (7E3) to the platelet GPIIb/IIIa complex was developed and subsequently demonstrated to produce an antithrombotic effect in dogs and monkeys when infused intravenously (8, 9) . The same antibody was then assessed in combination with tissue-type plasminogen acti-Aa chain FIG. 2. -Platelet aggregation is induced by a variety of blood-borne agonists such as ADP, collagen, thrombin, epinephrine, thromboxane A2, and serotonin which all interact with their specific platelet membrane receptors. Upon receptor stimulation and resulting signal transduction, glycoprotein IIb/IIIa (GPIIb/IIIa) is expressed on the platelet surface and binds fibrinogen. Binding of GPIIb/IIIa to fibrinogen occurs via a specific Arg-Gly-Asp (RGD) sequence located on the Aa chains of fibrinogen. Due to the dimeric nature of fibrinogen, platelet-to-platelet crosslinking occurs via this interaction and results in thrombus formation. vator (tPA) and was shown to accelerate thrombolysis in dogs and to prevent acute reocclusion (20, 46) . These actions to improve the efficiency of thrombolysis are related to the activation of platelets by thrombolytics (14, 32, 39) and the high degree of thrombogenicity that exists in diseased cor- onary arteries leading to reocclusive events. The 7E3 antibody, which is a F(ab')2 fragment, has been evaluated in preliminary clinical studies and has led to impressive suppression of ex vivo platelet aggregation and prolongation of the bleeding time (21) . However, once the antibody binds to the GPIIb/ Illa receptor on the platelet surface, the inhibition of platelet function is essentially irreversible due to the tight binding affinity of the antibody for the receptor (21 ) . Since platelets have a life span of 7-10 days, new platelets that enter the circulation restore the hemostatic state of the patient. Thus, once the antibody has been administered and platelet function inhibited, readily reversing the effect, if so desired, may not be possible. In the thrombolytic arena, where bleeding is a serious concern due to the potential of fatal or disabling intracranial hemorrhage, this approach will require careful safety evaluation before it is accepted into medical prac-tice. Due to lack of acute reversibility with the antibody directed approach, other means to interrupt platelet binding of fibrinogen via GPIIb/IIIa have been investigated that allow for rapid restoration of platelet function following termination of intravenous infusion of the agent.
As mentioned previously, platelet binding of plasma fibrinogen occurs through a specific RGD sequence in the Aa chain of fibrinogen. Thus, agents that contain an RGD sequence should be able to compete effectively with fibrinogen binding to the GPIIb/IIIa complex on the platelet surface. On this basis, viper venom peptides that contain RGD sequences have been identified and evaluated extensively as anti-thrombotic agents. A whole family of viper venom peptides has been extracted from crude venom and sequenced. Of these, the most notable are bitistatin from the venom of Bitis arientans (40) , trigramin from the venom of Trimeresurus gramineus (10, 26) , and echistatin from the venom of Echis carinatus (18) .
Trigramin is a 7 2-amino acid peptide that inhibits ADP-induced platelet aggregation with an ICso value of 1.3 x 10-7 M (26) and inhibits platelet hemostatic plug formation in vivo with a potency of almost 3 orders of magnitude greater than that achieved with authentic arginine-glycine-aspartic acid-serine (RGDS) itself (10, 38) . Echistatin and bitistatin are 49-and 83-amino acid-containing inhibitors of platelet aggregation with ICso values against human platelet aggregation in platelet-rich plasma induced by ADP of 101.3 ± 4.3 and 237.2 + 13.5 mvt, respectively (40, 41) . Echistatin and bitistatin inhibit platelet-dependent coronary thrombus formation in stenosed coronary arteries (40, 35) with dose-dependent elevation of the bleeding time and inhibition of ex vivo platelet aggregation. In a canine model of coronary thrombosis elicited by electrolytic injury to the endothelial surface of the blood vessel, echistatin (25) and bitistatin (42) are effective in improving tPA-induced thrombolysis with a greater incidence of reperfusion and a decrease in the time to reperfusion; these effects were significantly different from control animals given tPA alone. Furthermore, in these same studies, echistatin and bitistatin were extremely effective in preventing platelet-dependent acute reocclusion, which occurs after successful lysis in a high percentage of control animals, even in the presence of high-dose heparin. Thus, these studies demonstrate the importance of inhibiting platelet function concomitant and subsequent to coronary artery thrombolysis, such that incidence and time to reperfusion is improved and acute reocclusion reduced.
Viper venom peptidic inhibitors of platelet GPIIb/ Illa are effective pharmacological tools in which the anti-platelet activity of this approach can be evaluated experimentally (25, 42) . However, due to the large size of these inhibitors, which would preclude efficient production of material, and the possibility of immune responses being elicited by foreign proteins, these agents are not prime clinical candidates. They do serve a useful role as templates for smaller peptide and nonpeptide mimetics, which may be useful as pharmacological drugs if they maintain the biological specificity and activity of the larger natural venom peptides.
In an effort to develop a clinically useful antithrombotic agent against platelet GPIIb/IIIa, small peptide inhibitors containing an RGD sequence have been synthesized. Authentic RGDS is in itself antithrombotic but extremely high concentrations must be infused locally in order to demonstrate an effect in vivo (38) . This is presumably due to the low affinity of native RGDS for the GPIIb/IIIa receptor complex. Arginine-glycine-aspartic acid-O-methyltyrosine (RGDY) has been evaluated in a canine model of thrombosis/thrombolysis and was partially effective at a dose (4 mg/kg/min) that was 1,000 times greater than required with snake venom peptides such as bitistatin to achieve similar endpoints (24) . Thus, conformation and binding interactions are probably extremely important in determining the potency of these agents in vivo, as RGDS and RGDY are impotent compared to viper venom peptides that also contain the RGD sequence but demonstrate high potency. Other linear peptides have been synthesized that inhibit fibrinogen binding to platelets such as GPRP and mimetics of the fibrinogen y chain such as LGGAKQAGDV (36) .
In an attempt to design more potent small inhibitors of GPIIb/IIIa, cyclical peptides have been synthesized with the hope that these compounds will have greater activity than their linear RGD-containing predecessors. The first of these compounds is SKF-106,760, which is a tetrapeptide cyclized with penicillamine to produce a ring structure (30) . This compound displayed potent inhibition of platelet-dependent thrombus formation in stenosed canine coronary arteries (effective dose 1-3 mg/kg, iv) and accelerated streptokinase (SK)-induced thrombolysis from 34±8tol4±3 min. Furthermore, SKF-106,760 reduced acute platelet-dependent thrombotic reocclusion following successful lysis from 83% in the control group treated only with SK to 14% in the SKF-106,760 drug-treated group (30) . Peptide mimetics of RGD-containing peptides have also been synthesized in an attempt to gain greater plasma stability and oral activity. In the prototypic compound of this class, the RG dipeptide segment was replaced with a guanidine-octanoate moiety, and the terminal amino acid was replaced by phenethylamine. These substitutions led to SC-47,643, a compound that contains only 1 natural amino acid, aspartate (31 ) . Because this compound has no natural peptide bonds and has biological activity almost identical to known RGD-containing peptides, SC-47,643 is referred to as a peptide mimetic.
SC-47,643 inhibited platelet aggregation in response to a large array of platelet agonists in both washed and platelet-rich human plasma (31 ) . SC-47,643 also inhibited fibrinogen binding to activated platelets with an IC,o of 1.0 x 10-5 M. These biological actions are consistent with other known RGD-containing peptides that have previously been characterized as fibrinogen receptor antagonists. In vivo, SC-47,643 was effective in preventing collageninduced thrombocytopenia in rats (ED,, = 0.07 mg/ kg, T,/, = 36 min) and in dogs blocked collageninduced ex vivo platelet aggregatory responses by 50% following bolus injection of 1.7 mg/kg, iv. Steady-state infusions (ED,, = 0.03 mg/kg/min) had no effect on blood pressure, heart rate, or platelet count (31) . These data demonstrate that SC-47,643, a peptide mimetic of the natural fibrinogen RGD binding sequence, is capable of blocking plateletfibrinogen interactions and platelet aggregation induced by multiple mediators.
Fibrinogen receptor antagonism represents a novel approach to inhibition of platelet aggregation as multiple mediators of aggregation will be affected by interruption of the final common pathway (i.e., binding of plasma fibrinogen). Clinical conditions potentially under evaluation for this indication would be restenosis following percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafting (CABG) and as an adjunct to thrombolysis. Abrupt closure following PTCA, CABG, and thrombolysis has been attributable to platelet-dependent thrombosis, and currently aspirin is the agent of choice. However, even in the presence of aspirin and heparin, 15-20% of patients successfully reperfused with thrombolytic drugs reocclude in hours to days following successful recanalization. Thus, agents with a broader spectrum of activity (i.e., fibrinogen receptor antagonists) may serve to decrease the reocclusion rate following pharmacological thrombolysis.
Restenosis is the chronic process of blood vessel closure following successful PTCA. Restenosis refers specifically to smooth muscle cell proliferation at the site of balloon dilatation, which eventually leads to reclosure of the vessel. This process may be initiated by growth factors that reside in platelets and/or smooth muscle such as platelet-derived growth factor (PDGF). Thus, elimination of platelet adherence/aggregation by fibrinogen receptor antagonism may eliminate an important growth factor (PDGF) from acting locally on smooth muscle cells at the injured site to induce proliferation. It still must be determined what appropriate treatment duration is required as the restenosis process itself takes 4-6 mo, and it is not clear whether acute therapy immediately following balloon dilation will result in long-term benefit or chronic therapy in this condition will be required.
DISCUSSION
Aspirin is one of the most commonly utilized drugs in medicine and has been conclusively demonstrated to exert important protective actions against cardiovascular disease. The side effect profile of aspirin and aspirinlike drugs involves mainly gastrointestinal upset due to inhibition of cytoprotective prostaglandins in the gut mucosa. Aspirin exerts little risk of bleeding diathesis, as bleeding time is elevated approximately 2-fold maximally with no significant effect on platelet count. Thus, aspirin is safe and effective and has an extremely low cost of goods. However, aspirin has a relatively narrow range of activity as a platelet inhibitory drug because it interferes only with cyclooxygenase-dependent platelet agonists such as thromboxane. Besides blocking the formation of thromboxane, aspirin also attenuates formation of vasodilatory and anti-aggregatory prostacyclin. Nonetheless, thromboxane is an extremely potent and ubiquitous agent and plays a major role in initiating thromboxane receptor-mediated platelet aggregation as well as elicits platelet release reaction or so-called secondary aggregation. Undoubtedly, these effects of aspirin against the actions of thromboxane are involved in the protective mechanism of aspirin in prevention of cardiovascular disease.
Fibrinogen receptor antagonism is a relatively new development that originated with identification of a glycoprotein (GPIIb/IIIa) on platelets that recognized a distinct epitope on fibrinogen (RGD). The first pharmacological probe of this receptor was a monoclonal antibody developed by Coller (9) , which effectively blocked platelet aggregation in vitro to all known platelet agonists. Clinical trials with this antibody (7E3) have led to impressive suppression of ex vivo platelet aggregation in patients with unstable angina (22) . The 7E3 antibody binds tightly and with high affinity to the platelet GPIIb/IIIa integrin complex such that prolonged perturbation ( > 48 hr) of platelet function results accompanied by increased template bleeding times.
Due to the difficulty of preparing clinical grade quantities of antibody, many investigators have turned to development of small RGD-based pep-tides and peptide-based mimetics as therapeutics. This work originated with the observation that certain viper venom peptides were anti-thrombotic by virtue of an RGD sequence in the peptide (26) . Small, cyclic peptides have subsequently been developed and exhibit potency and efficacy that is undistinguishable from the viper venom peptides and monoclonal antibodies (30) . However, the small cyclic peptides have half-lives in the circulation that are much shorter than the 7E3 antibody and, thus, platelet function can be quickly restored to baseline by termination of the iv infusion.
In summary, it will be interesting to follow the development of fibrinogen receptor antagonists as novel anti-thrombotic therapies for potential use in unstable angina, peripheral vascular disease, thrombolysis, and stroke. However, inasmuch as the fibrinogen receptor antagonists have a potential advantage over aspirin due to a broader spectrum of anti-platelet activity, they may also have a potential disadvantage in that bleeding time is elevated quite significantly and could potentially lead to serious bleeding complications. Thus, the risk-benefit ratio must be carefully evaluated in the use of fibrinogen receptor antagonists over the use of standard aspirin in the aggressive management of platelet-dependent cardiovascular diseases.
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